Therapeutic Vaccination Strategies

  • P. Walden
  • W. Sterry
  • H. Hennekes
Conference proceedings

Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 30)

Table of contents

  1. Front Matter
    Pages I-XV
  2. P. Walden
    Pages 7-22
  3. J. W. Hodge, J. Schlom
    Pages 23-52
  4. S. R. Riddell, E. H. Warren, D. Lewinsohn, H. Mutimer, M. Topp, L. Cooper et al.
    Pages 53-73
  5. P. Romero, M. J. Pittet, D. Valmori, D. E. Speiser, V. Cerundolo, D. Liénard et al.
    Pages 75-97
  6. A. M. Krieg
    Pages 105-118
  7. F. K. Stevenson, D. Zhu, M. B. Spellerberg, J. Rice, C. A. King, A. R. Thompsett et al.
    Pages 119-136
  8. U. Trefzer, G. Herberth, W. Sterry, P. Walden
    Pages 155-166
  9. Back Matter
    Pages 191-195

About these proceedings


The induction of immune responses against tumor cells by vaccination is rapidly evolving as a therapeutic modality with new potentials for the treatment of cancer. It is based on the fact that our immune system can identify tumor cells and, once activated, is capable of developing specific immunity against the neoplastic cells. Numerous observations and intense research clearly document the major contribution of the immune system to the prevention of cancer. And there are many re­ ports of patients suffering from malignant melanoma or other tumors who mount a spontaneous immune response against their tumor cells that results in tumor regression. Based on the recent advances in our understanding of the compo­ nents of our immune system, their interactions and the regulation of immune responses, we are now able to design vaccination strategies that induce or enhance cell-mediated immunity against tumors. A ma­ jor advancement came with the identification and characterization of relevant tumor antigens, which are suitable target structures for anti-tu­ mor immune response. First clinical trials using such vaccine strategies have yielded encouraging results in patients. However, in spite of many reported cases of successful therapy of cancer by vaccination many patients still do not experience relief after such treatments. These initial clinical trials and the accompanying investigations have revealed a number of important results that indicate the direction of future re­ search and development in the field.


Antigen Autoimmunerkrankungen Melanom Tumortherapie auto-immune disease autoimmune disease gene therapy melanoma therapeutische Vakzinirung tumour therapy vaccination therapy

Editors and affiliations

  • P. Walden
    • 1
  • W. Sterry
    • 1
  • H. Hennekes
    • 2
  1. 1.Department of Dermatology and Allergy, Medical Faculty CharitéHumboldt UniversityBerlinGermany
  2. 2.Experimental DermatologySchering AGBerlinGermany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2000
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-662-04185-7
  • Online ISBN 978-3-662-04183-3
  • Series Print ISSN 0947-6075
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Internal Medicine & Dermatology
Consumer Packaged Goods